| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 155, Issue 10 5038-5045, Copyright © 1995 by American Association of Immunologists
ARTICLES |
AF Suffredini, D Reda, SM Banks, M Tropea, JM Agosti and R Miller
Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Effects of dimeric TNF receptor (p80) Fc (TNFR:Fc) on acute phase responses were evaluated in 18 volunteers given endotoxin (4 ng/kg i.v.). Subjects were randomized to receive either placebo (n = 6), low dose TNFR:Fc (10 mg/m2 i.v., n = 6), or high dose TNFR:Fc (60 mg/m2 i.v., n = 6). TNFR:Fc blocked plasma TNF bioactivity (p = 0.001) and increased, in a dose-ordered fashion, TNF immunoactivity (p < 0.001). TNFR:Fc decreased secondary cytokine levels including IL-1 beta (p = 0.007), IL-8 (p < 0.001), IL-1 receptor antagonist (p < 0.001), granulocyte-CSF (p = 0.03), and growth regulated peptide-alpha (p = 0.001) but not macrophage inflammatory protein-1 alpha or IL-10. Low dose, but not high dose, TNFR:Fc blunted or delayed the release of epinephrine and cortisol (p < or = 0.026). Despite the absence of plasma TNF bioactivity, high dose TNFR:Fc was less immunosuppressive than low dose TNFR:Fc as measured by cytokine and stress hormone responses. Endotoxin-related symptoms were not altered by TNFR:Fc and the febrile response was delayed but not diminished (p = 0.004). Increases in cardiac index (72 +/- 19%) and heart rate (60 +/- 10%) and decreases in systemic vascular resistance index (47 +/- 7%) were unaltered by TNFR:Fc. These data suggest that the inflammatory response to endotoxin can escape from high levels of circulating TNF-blocking activity and redundant pathways, independent of circulating TNF, can sustain inflammation and clinical responses caused by acute endotoxemia.
This article has been cited by other articles:
|
|
 |
|
  M. T. Kasaian, X.-Y. Tan, M. Jin, L. Fitz, K. Marquette, N. Wood, T. A. Cook, J. Lee, A. Widom, R. Agostinelli, et al. Interleukin-13 Neutralization by Two Distinct Receptor Blocking Mechanisms Reduces Immunoglobulin E Responses and Lung Inflammation in Cynomolgus Monkeys J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 882 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Robertson, A. S. Care, and R. J. Skinner Interleukin 10 Regulates Inflammatory Cytokine Synthesis to Protect Against Lipopolysaccharide-Induced Abortion and Fetal Growth Restriction in Mice Biol Reprod, May 1, 2007; 76(5): 738 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Weaver, P. A. Pioli, K. Wardwell, S. N. Vogel, and P. M. Guyre Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors J. Leukoc. Biol., March 1, 2007; 81(3): 663 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Marsik, R. Sunder-Plassmann, B. Jilma, F. M. Kovar, C. Mannhalter, O. Wagner, H. Rumpold, and G. Endler The C-Reactive Protein +1444C/T Alteration Modulates the Inflammation and Coagulation Response in Human Endotoxemia Clin. Chem., October 1, 2006; 52(10): 1952 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Sarzi-Puttini, F Atzeni, A Doria, L Iaccarino, and M Turiel Tumor necrosis factor-a, biologic agents and cardiovascular risk Lupus, September 1, 2005; 14(9): 780 - 784. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Zhou Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein J. Clin. Pharmacol., May 1, 2005; 45(5): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jit, B. Henderson, M. Stevens, and R. M. Seymour TNF-{alpha} neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome Rheumatology, March 1, 2005; 44(3): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Copeland, H. S. Warren, S. F. Lowry, S. E. Calvano, D. Remick, and the Inflammation and the Host Response to Injury I Acute Inflammatory Response to Endotoxin in Mice and Humans Clin. Vaccine Immunol., January 1, 2005; 12(1): 60 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Dinarello Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed Innate Immunity, August 1, 2004; 10(4): 201 - 222. [Abstract] [PDF]
|
|
|
|
|
|
E. Liang, Y. N. Wong, I. Allen, R. Kao, M. Marino, and C. DiLea Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function J. Clin. Pharmacol., December 1, 2003; 43(12): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Beishuizen and L. G. Thijs Review: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis Innate Immunity, February 1, 2003; 9(1): 3 - 24. [Abstract] [PDF]
|
|
|
|
 |
|
 D. L. Mann Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future Circ. Res., November 29, 2002; 91(11): 988 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soop, H. Duxbury, A. O Agwunobi, J. M. Gibson, S. J. Hopkins, C. Childs, R. G. Cooper, P. Maycock, R. A. Little, and G. L. Carlson Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans Am J Physiol Endocrinol Metab, June 1, 2002; 282(6): E1276 - E1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brandtzaeg, A. Bjerre, R. Ovstebo, B. Brusletto, G. B. Joo, and P. Kierulf Invited review: Neisseria meningitidis lipopolysaccharides in human pathology Innate Immunity, December 1, 2001; 7(6): 401 - 420. [Abstract] [PDF]
|
|
|
|
|
|
C. Fiuza and A. F. Suffredini Human models of innate immunity: local and systemic inflammatory responses Innate Immunity, October 1, 2001; 7(5): 385 - 388. [Abstract] [PDF]
|
|
|
|
 |
|
 N. P. O'GRADY, H. L. PREAS II, J. PUGIN, C. FIUZA, M. TROPEA, D. REDA, S. M. BANKS, and A. F. SUFFREDINI Local Inflammatory Responses following Bronchial Endotoxin Instillation in Humans Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1591 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verbon, P. E. P. Dekkers, T. ten Hove, C. E. Hack, J. P. Pribble, T. Turner, S. Souza, T. Axtelle, F. J. Hoek, S. J. H. van Deventer, et al. IC14, an Anti-CD14 Antibody, Inhibits Endotoxin-Mediated Symptoms and Inflammatory Responses in Humans J. Immunol., March 1, 2001; 166(5): 3599 - 3605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. V. Williams, T. Fullerton, J. C. Fox, M. B. Enslin, L. Murray, and D. Jorkasky Asystole following endotoxin administration Innate Immunity, August 1, 2000; 6(4): 303 - 306. [PDF]
|
|
|
|
 |
|
 P. E. P. Dekkers, M. Levi, S. J. H. van Deventer, and T. van der Poll Divergent Roles of Tumor Necrosis Factor and Platelet-Activating Factor in Endotoxin-Induced Release of Monocyte Chemoattractant Protein 1 and Macrophage Inflammatory Protein 1beta in Chimpanzees Infect. Immun., October 1, 1999; 67(10): 5480 - 5482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E.P. Dekkers, F. N. Lauw, T. ten Hove, A. A. te Velde, P. Lumley, D. Becherer, S. J.H. van Deventer, and T. van der Poll The Effect of a Metalloproteinase Inhibitor (GI5402) on Tumor Necrosis Factor-alpha (TNF-alpha ) and TNF-alpha Receptors During Human Endotoxemia Blood, October 1, 1999; 94(7): 2252 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pugin, M.-C. Widmer, S. Kossodo, C.-M. Liang, H. L. Preas II, and A. F. Suffredini Human Neutrophils Secrete Gelatinase B In Vitro and In Vivo in Response to Endotoxin and Proinflammatory Mediators Am. J. Respir. Cell Mol. Biol., March 1, 1999; 20(3): 458 - 464. [Abstract] [Full Text]
|
|
|
|
|
|
B. JILMA, A. BLANN, T. PERNERSTORFER, P. STOHLAWETZ, H.-G. EICHLER, B. VONDROVEC, J. AMIRAL, V. RICHTER, and O. F. WAGNER Regulation of Adhesion Molecules during Human Endotoxemia . No Acute Effects of Aspirin Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 857 - 863. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. van der Poll, E. Endert, S. M. Coyle, J. M. Agosti, and S. F. Lowry Neutralization of TNF does not influence endotoxininduced changes in thyroid hormone metabolism in humans Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1999; 276(2): R357 - R362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Smith, S. J. Skerrett, E. Y. Chi, M. Jonas, K. Mohler, and C. B. Wilson The locus of tumor necrosis factor-alpha action in lung inflammation. Am. J. Respir. Cell Mol. Biol., December 1, 1998; 19(6): 881 - 891. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Chirinos-Rojas, M. W. Steward, and C. D. Partidos A Peptidomimetic Antagonist of TNF-{alpha}-Mediated Cytotoxicity Identified from a Phage-Displayed Random Peptide Library J. Immunol., November 15, 1998; 161(10): 5621 - 5626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Schultz, P. Speelman, S. Zaat, S. J. H. van Deventer, and T. van der Poll Erythromycin Inhibits Tumor Necrosis Factor Alpha and Interleukin 6 Production Induced by Heat-Killed Streptococcus pneumoniae in Whole Blood Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1605 - 1609. [Abstract] [Full Text]
|
|
|
|
|
|
G. R. Hill, J. M. Crawford, K. R. Cooke, Y. S. Brinson, L. Pan, and J. L.M. Ferrara Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines Blood, October 15, 1997; 90(8): 3204 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. van der Poll, S. M. Coyle, M. Levi, P. M. Jansen, M. Dentener, K. Barbosa, W. A. Buurman, C. E. Hack, J. W. ten Cate, J. M. Agosti, et al. Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans Blood, May 15, 1997; 89(10): 3727 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Fidel Jr, R. Romero, J. Cutright, N. Wolf, R. Gomez, H. Araneda, M. Ramirez, and B. H. Yoon Treatment With the Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein Does Not Prevent Endotoxin-Induced Preterm Parturition in Mice Reproductive Sciences, January 1, 1997; 4(1): 22 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Nicoletti, P. Zaccone, R. Di Marco, M. Lunetta, G. Magro, S. Grasso, P. Meroni, and G. Garotta Prevention of Spontaneous Autoimmune Diabetes in Diabetes-Prone BB Rats by Prophylactic Treatment with Antirat Interferon-{gamma} Antibody Endocrinology, January 1, 1997; 138(1): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
